December 2002 | ||||||
Sun | Mon | Tue | Wed | Thu | Fri | Sat |
1 | 2 | 3 | 4 | 5 | 6 | 7 |
8 | 9 | 10 | 11 | 12 | 13 | 14 |
15 | 16 | 17 | 18 | 19 | 20 | 21 |
22 | 23 | 24 | 25 | 26 | 27 | 28 |
29 | 30 | 31 | ||||
Nov Jan |
The Whole Biochip: Why?
The practical result of this technology will include: personalized medicines that are tailored directly to an individuals needs; the treatment of diseases at the molecular level, long before external symptoms appear; and the development of multi-factor drugs that regulate both the protein process in question as well as their regulators. The cost savings for health care organizations, the potential for huge blockbuster treatments, and whole new areas of profit accumulation will mean the power of capital to fund innovation and research in this area will help the underlying technologies of the whole biochip to become a reality in the next 15-20 years. The results for life and health expectancy should be tremendous. The first part of the biochip that has moved into the mass production phase is the DNA microarray. Think: transistor, microprocessor, semiconductor, computer, network.
6:35:51 PM comment []